4:42 PM ET
8-K
Deal Termination
Supernus Pharmaceuticals Deal Termination with UBS Bank USA
Supernus Pharmaceuticals terminated its uncommitted demand revolving credit line with UBS Bank USA on October 20, 2026. The termination was made in anticipation of the company's pending merger with Indivior Pharmaceuticals and the establishment of a new senior secured credit facility for the combined entity. There were no outstanding borrowings or early termination penalties associated with the cancellation.
- Counterparty
- UBS Bank USA